Recent developments
Oncology therapies
In hematologic malignancies, TECVAYLI® plus DARZALEX FASPRO® and CARVYKTI® in earlier lines reported durable benefits in myeloma, while Columvi and GemOx and Lunsumio combination regimens underscored bispecific progress in lymphoma. EPKINLY + R2 and epcoritamab trials expanded data, including Richter Transformation treatment. For CLL/SLL, expanded approval for Jaypirca and the BRUIN CLL-313 trial reinforced BTK pathway strategies.
Solid tumor progress
Roche’s giredestrant as an adjuvant endocrine treatment showed reduced invasive recurrence in ER+/HER2– early breast cancer. In urology, the gemcitabine intravesical system one-year disease-free survival supported a bladder-sparing approach in BCG-unresponsive NMIBC. Pipeline breadth expanded as Takeda finalized a license and collaboration agreement with Innovent Biologics for IBI363 and IBI343 in solid tumors.
Immunology and fibrosis
Autoimmune and fibrotic care advanced with EU approval of Gazyva in lupus nephritis and EC clearance of IMAAVY® (nipocalimab) for gMG. In interstitial lung disease, China approved JASCAYD® (nerandomilast) for PPF. Hematology saw durable phlebotomy-sparing control with rusfertide in polycythemia vera.
Metabolic therapies and capacity
Obesity pipelines and access evolved: BI 3034701, a long-acting triple-agonist peptide entered mid-stage testing, Wegovy 7.2 mg was filed for expedited review, and price reduction for Zepbound vials was announced via LillyDirect. Capacity aligned with demand through Lilly’s $6 billion Alabama API facility and portfolio expansion via Novo Nordisk’s acquisition of Akero Therapeutics.
Diagnostics and testing
Roche expanded decentralized testing with the cobas BV/CV assay for vaginitis and a point-of-care Bordetella PCR delivering 15-minute results. These assays integrate with cobas workflows and address rising STI and pertussis burdens.
Manufacturing and deals
Supply chains and portfolios shifted: Croda partnered with Amino on high-purity amino acids; WuXi Biologics’ CRDMO expansion to Qatar progressed; Aptar acquired Sommaplast for oral dosing; CABB sold Jayhawk to Anupam Rasayan; and Asahi Kasei divested Daramic. Energy sourcing advanced through an Iberdrola–Bayer power and heat purchase agreements. R&D enablement included Lilly and Indiana University’s trial access collaboration and Lilly’s acquisition of Adverum, while Genmab appointed a France GM.